A detailed history of Alyeska Investment Group, L.P. transactions in Intra Cellular Therapies, Inc. stock. As of the latest transaction made, Alyeska Investment Group, L.P. holds 1,394,532 shares of ITCI stock, worth $119 Million. This represents 0.58% of its overall portfolio holdings.

Number of Shares
1,394,532
Previous 251,920 453.56%
Holding current value
$119 Million
Previous $17.4 Million 447.91%
% of portfolio
0.58%
Previous 0.11%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$64.76 - $79.84 $74 Million - $91.2 Million
1,142,612 Added 453.56%
1,394,532 $95.5 Million
Q1 2024

May 15, 2024

BUY
$64.37 - $75.65 $8.57 Million - $10.1 Million
133,137 Added 112.08%
251,920 $17.4 Million
Q4 2023

Feb 14, 2024

BUY
$46.37 - $73.65 $3.75 Million - $5.95 Million
80,783 Added 212.59%
118,783 $8.51 Million
Q2 2023

Aug 14, 2023

SELL
$54.67 - $66.44 $656,040 - $797,280
-12,000 Reduced 24.0%
38,000 $2.41 Million
Q1 2023

May 15, 2023

BUY
$43.8 - $56.99 $2.19 Million - $2.85 Million
50,000 New
50,000 $2.71 Million
Q4 2020

Feb 16, 2021

SELL
$23.34 - $32.22 $7.89 Million - $10.9 Million
-337,839 Reduced 60.73%
218,473 $6.95 Million
Q3 2020

Nov 16, 2020

BUY
$17.61 - $31.86 $5.07 Million - $9.17 Million
287,912 Added 107.27%
556,312 $14.3 Million
Q2 2020

Aug 14, 2020

SELL
$14.35 - $26.64 $3 Million - $5.57 Million
-209,026 Reduced 43.78%
268,400 $6.89 Million
Q1 2020

May 15, 2020

SELL
$12.31 - $33.12 $880,521 - $2.37 Million
-71,529 Reduced 13.03%
477,426 $7.34 Million
Q3 2017

Nov 14, 2017

BUY
$10.77 - $22.1 $5.91 Million - $12.1 Million
548,955
548,955 $8.66 Million

Others Institutions Holding ITCI

About Intra-Cellular Therapies, Inc.


  • Ticker ITCI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 94,401,696
  • Market Cap $8.07B
  • Description
  • Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in dev...
More about ITCI
Track This Portfolio

Track Alyeska Investment Group, L.P. Portfolio

Follow Alyeska Investment Group, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Alyeska Investment Group, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Alyeska Investment Group, L.P. with notifications on news.